@Article{or.2026.076384,
AUTHOR = {Renata Pacholczak-Madej, Mirosława Püsküllüoğlu, Anna Polakiewicz-Gilowska, Małgorzata Pieniążek, Iveta Kolářová, Miroslava Malejčíková, Lenka Rušinová, Miloš Holánek, Renata Soumarová, Karolina Winsko-Szczęsnowicz, Justyna Żubrowska, Aleksandra Konieczna, Agnieszka Młodzińska, Daniel Krejčí, Iwona Danielewicz, Magdalena Szymanik-Resko, Tomasz Ciszewski, Maja Lisik-Habib, Anika Pękala, Hana Študentová, Jan Šustr, Bogumiła Czartoryska-Arłukowicz, Aleksandra Łacko, Jolanta Smok-Kalwat, Michał Jarząb, Zuzana Bielčiková, Marcin Kubeczko},
TITLE = {Impact of Germline <i>BRCA1/2</i> Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan—An International CEBCC Study from Poland, the Czech Republic and Slovakia},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/26599},
ISSN = {1555-3906},
ABSTRACT = {<b>Background:</b> Germline breast cancer susceptibility gene 1/2 (<i>BRCA1/2</i>) variants guide breast cancer treatment, but their clinical relevance in metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) remains unclear. The study aimed to evaluate the association between <i>BRCA</i> status and outcomes in SG-treated mTNBC. <b>Methods:</b> We retrospectively analyzed 264 patients with mTNBC and known germline <i>BRCA1/2</i> (<i>gBRCA1/2</i>) status who received SG between August 2021 and May 2025 across multiple oncology centers in Poland, the Czech Republic and Slovakia. Survival outcomes were compared between patients with g<i>BRCA1/2</i> mutations (<i>gBRCA1/2m</i>) and those with g<i>BRCA1/2</i> wild-type (g<i>BRCA1/2</i>wt) using Kaplan–Meier estimates, the log-rank test, and multivariable Cox proportional hazards models. Two-sided <i>p</i> &lt; 0.05 was considered statistically significant. <b>Results:</b> Among 264 patients, 35 (13.3%) were g<i>BRCA1/2</i>m and 229 (86.7%) were g<i>BRCA1/2</i>wt. After a median follow-up of 9.9 months, the median progression-free survival (PFS) was 4.5 months (95% confidence interval [CI] 2.1–6.3) in g<i>BRCA1/2</i> carriers versus 4.2 months (95% CI 3.5–5.8) in g<i>BRCA1/2</i>wt patients (<i>p</i> = 0.10). Median overall survival (OS) was 9.1 months (95% CI 5.0–15.1) in g<i>BRCA1/2</i> carriers compared to 11.5 months (95% CI 10.3–13.5) in g<i>BRCA1/2</i>wt patients (<i>p</i> = 0.26). Brain metastases were more frequent in carriers (20% vs. 8.3%, <i>p</i> = 0.06). In multivariable analysis, Eastern Cooperative Oncology Group (ECOG) performance status was the only independent predictor of poorer survival (hazard ratio 1.97, 95% CI 1.42–2.74, <i>p</i> &lt; 0.01), while g<i>BRCA1/2</i> status showed no independent association. <b>Conclusions:</b> In this large retrospective cohort of mTNBC patients treated with SG, the presence of g<i>BRCA1/2</i> was not associated with statistically significant differences in PFS or OS.},
DOI = {10.32604/or.2026.076384}
}